Moderna Q2 2025 Earnings Forecast
Moderna Lowers 2025 Revenue Outlook on U.K. Vaccine Shipment Delay, But Beats Q2 Expectations
Table of Contents
Moderna’s shares fell more than 9% on Friday after the biotech company announced it was lowering the high end of its 2025 revenue outlook due to a delay in vaccine shipments to the U.K. Despite this adjustment, Moderna managed to beat Wall Street’s expectations for the second quarter, driven by cost-cutting measures.
The company now projects its full-year revenue to be between $1.5 billion adn $2.2 billion, a reduction of $300 million at the upper end of the previous range. This news follows Moderna’s recent announcement of plans to cut 10% of its workforce,signaling a broader strategy to manage costs amid declining Covid vaccine sales and efforts to diversify its product pipeline.
U.K. Shipment Shift Impacts revenue Outlook
Moderna Chief Financial Officer Jamey Mock explained that the revised outlook is primarily due to a shift in vaccine deliveries to the U.K. Instead of shipping spring Covid boosters at the end of 2025, these shipments are now scheduled for the first quarter of 2026.Mock emphasized that this change does not affect the overall contract value between Moderna and the U.K.
“it’s just moving deliveries from our fiscal year-end into their fiscal year-end, which happens to be the first quarter of next year, to fulfill supply for the spring booster in the U.K.,” Mock stated in an interview.
Q2 Financial Performance Exceeds Analyst Estimates
On a more positive note, Moderna reported a narrower-than-expected loss per share and revenue that surpassed analyst forecasts for the second quarter.Here’s a breakdown of Moderna’s second-quarter results compared to Wall Street expectations, according to LSEG data:
Loss per share: $2.13 versus an expected loss of $2.97
Revenue: $142 million versus $113 million expected
Moderna posted second-quarter sales of $142 million,marking a 41% decrease from the same period in the prior year.This decline is attributed to lower Covid vaccine sales.The company’s Covid shot generated $114 million in revenue for the quarter, exceeding the $89 million anticipated by analysts.
However,the company’s vaccine for respiratory syncytial virus (RSV) saw “negligible” sales,falling short of the $5.9 million expected by analysts.
The company reported a net loss of $825 million, or $2.13 per share, for the second quarter. This is an advancement compared to the net loss of $1.3 billion, or $3.33 per share, recorded in the year-ago period.
Cost-Cutting Measures Drive Q2 Beat
Mock attributed the company’s ability to beat quarterly estimates to its successful cost-cutting initiatives. He highlighted that second-quarter operating expenses decreased by 27% to $1.1 billion, down from $1.6 billion in the same period last year.
“If there’s anything to really read into, from a first half [of 2025] outlook, from a financial perspective, it’s on the cost side,” Mock commented.